{"id":388340,"date":"2020-11-25T07:03:19","date_gmt":"2020-11-25T12:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388340"},"modified":"2020-11-25T07:03:19","modified_gmt":"2020-11-25T12:03:19","slug":"anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","title":{"rendered":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  25, 2020  (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President &amp; Chief Executive Officer, Christopher U. Missling, PhD, will present at the virtual Evercore ISI 3<sup>rd<\/sup> Annual HealthCONx Conference on Thursday, December 3, 2020 at 11:45 a.m. ET.<\/p>\n<p align=\"justify\">The fireside chat will be webcast live and can be accessed through the following link <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9A5wOzL9Ejeu3EJHNElg1_ZuIfCiCPkkmUADERlt3FwEPSrlI25IgCrFlPKze2K4sQMp1jGTFr3-_WJpwW1ruAlxBuWRnfQgJ4F5lNBNhx2mx8Slz_tc-_u1yN-YDHa9C8hDYj9n55-1-s3nllynlYCX8_z_Yc8zSDzF9tvhhik=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/wsw.com\/webcast\/evercore11\/avxl\/2380047<\/a> or by visiting the investors section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eRCtagZKOHn7vtjAcQmu5189CHI8hRg3yTq7CVVVaEcLIlbRn8RdvwnjIOTqyL9wGpIVg0IUJv873WJjbNNZ-g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.anavex.com<\/a>. The webcast will be archived for a period of 30 days following the conclusion of the live event.<\/p>\n<p>\n        <strong>About Anavex Life Sciences Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex\u2019s lead drug candidate, ANAVEX\u00ae2-73 (<em>blarcamesine<\/em>), recently completed a successful Phase 2a clinical trial for Alzheimer\u2019s disease. ANAVEX\u00ae2-73 (<em>blarcamesine<\/em>) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and\/or reverse the course of Alzheimer\u2019s disease. ANAVEX\u00ae2-73 (<em>blarcamesine<\/em>) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson\u2019s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae2-73 (<em>blarcamesine<\/em>) for the treatment of Parkinson\u2019s disease. ANAVEX\u00ae3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer\u2019s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX\u00ae3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eRCtagZKOHn7vtjAcQmu52eSLorsMsnv3UOg1pRTSbXR3aL00HISucqTs3qv9v1tMGv7P5uEPZBTyNEqfaTthQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.anavex.com<\/a>. You can also connect with the company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r4nfQCOu84H56_aGffkDSB7DpcNnZw6w6IoMDD3Ru5TMX8UtIrznyJFuKgxGs0q2YG8u8iRuCIbPPuttsfBT5g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter,<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t-WOaEA283Gb6UNhLh9-p0WJbuMcT2jAPXSvZWvcsCB_8VojVnFOZeKQEcBnGE9elQ2WwTtIqEF1qvi9XSD1mWnbDQfALWEcixezGaLjqUauu8Kl4R4oskYK3oywLwZbU3UpOf2DLngHkuAzH-LKKg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w7gLUAWrU9nr9VfJLKrp8FFroniUD7A0799AJcXa5tPHxCnZSwQMfoRHkOUlO7PlKpXv3n9rZiRB-ff4xXwpy4feFot0UoT5cbwvxMfrFsgETwx-Smmpd7-Su2OuyZYe\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n<p align=\"justify\">\n        <strong>For Further Information:<\/strong>\n      <\/p>\n<p align=\"justify\">Anavex Life Sciences Corp.<br \/>Research &amp; Business Development<br \/>Toll-free: 1-844-689-3939<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6kWXhH0ZzhIsGgZi_8KxAilG7NvD-PHQ-X9pooxJvBNe_1YPz_AiR77pNPzB4D9Zq_H409OXPWHZtKOeclrHMQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@anavex.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investors &amp; Media:<\/strong><br \/>\n        <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d0Et23tbrkubtptAsNvxGg8MRpwZw1rp8TkgdfDIlB-C04mHd0wQ8OjCGvzS6Xoxqh3TTol2vyr0TEkCwQX74Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@anavex.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6b674eec-8537-4cc0-a9cb-1e7ff2e4910a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President &amp; Chief Executive Officer, Christopher U. Missling, PhD, will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 11:45 a.m. ET. The fireside chat will be webcast live and can be accessed through the following link https:\/\/wsw.com\/webcast\/evercore11\/avxl\/2380047 or by visiting the investors section of the company&#8217;s website at www.anavex.com. The webcast will be archived for a period of 30 days following &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388340","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President &amp; Chief Executive Officer, Christopher U. Missling, PhD, will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 11:45 a.m. ET. The fireside chat will be webcast live and can be accessed through the following link https:\/\/wsw.com\/webcast\/evercore11\/avxl\/2380047 or by visiting the investors section of the company&#8217;s website at www.anavex.com. The webcast will be archived for a period of 30 days following &hellip; Continue reading &quot;Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T12:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference\",\"datePublished\":\"2020-11-25T12:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"},\"wordCount\":535,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\",\"name\":\"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\",\"datePublished\":\"2020-11-25T12:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","og_description":"NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer\u2019s disease, Parkinson\u2019s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President &amp; Chief Executive Officer, Christopher U. Missling, PhD, will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 at 11:45 a.m. ET. The fireside chat will be webcast live and can be accessed through the following link https:\/\/wsw.com\/webcast\/evercore11\/avxl\/2380047 or by visiting the investors section of the company&#8217;s website at www.anavex.com. The webcast will be archived for a period of 30 days following &hellip; Continue reading \"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-25T12:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference","datePublished":"2020-11-25T12:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"},"wordCount":535,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/","name":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=","datePublished":"2020-11-25T12:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkwNyMzODQzMTA1IzIwMTk1Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388340"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388340\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}